Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast Phase 2 in Rheumatoid Arthritis (Inadequate Response to Methotrexate)
NCT01285310Phase 2Terminated
- Sponsor
- Amgen
- Start
- Dec 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of apremilast in rheumatoid arthritis (RA), sponsored by Amgen. Started Dec 2010; status: terminated.
02
Drugs
apremilast
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01285310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01285310.